Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

NCT01462266 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin
DRUG: Comparator: Placebo
BIOLOGICAL: Insulin Glargine
DRUG: Metformin

Sponsor

Merck Sharp & Dohme LLC